Methods| The French Health Products Agency (ANSM) allows compassionate use of
promising off-label drugs without available therapeutic alternatives. Children throughout …

OBJECTIVES: The safety of oral propranolol for infantile hemangioma has not yet been
studied at population level since the pediatric use marketing authorization was obtained in …

METHODS: We searched Embase and Medline databases (2007–July 2014) and
unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric …

Importance Propranolol for infantile hemangiomas (IH) has been shown to be effective and
relatively safe. However, other less lipophilic β-blockers, such as nadolol, may be preferable …

Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has
been well documented, there is a paucity of clinical data regarding the safety and tolerance …

Nadolol is a b-adrenergic antagonist that has been shown to be efficacious in the treatment
of infantile hemangioma. It has been suggested that this drug may have fewer side effects …

Importance Propranolol has become the first-line therapy for problematic infantile
hemangiomas (IHs) that require systemic therapy. However, different adverse events have …

In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been
discovered serendipitously by Léauté‐Labrèze and her coworkers. Since then, propranolol …

Background Oral propranolol has been used to treat complicated infantile hemangiomas,
although data from randomized, controlled trials to inform its use are limited. Methods We …

Background Initial propranolol recommendations for infantile hemangioma published in
2013 were intended as provisional best practices to be updated as evidence-based data …